Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu [Yahoo! Finance]
Traws Pharma, Inc. (TRAW)
Company Research
Source: Yahoo! Finance
Phase 1 dosing completed in healthy volunteers Potent inhibition of drug-resistant and bird flu viruses in vitro In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs Phase 2 study expected to begin in H1 2025 Traws Pharma is expanding its influenza program to address the potential threat of bird flu NEWTOWN, Pa. Dec. 23, 2024 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. "The spread of avian influenza in wild and domestic animal populations including mammals, brings increasing risk for adaptation to humans and subsequent spread in the popul
Show less
Read more
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird FluPR Newswire
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswire
- Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza TreatmentPR Newswire
- Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir MarboxilGlobeNewswire
TRAW
Earnings
- 11/14/24 - Miss
TRAW
Sec Filings
- 12/20/24 - Form 8-K
- 11/22/24 - Form 8-K
- 11/15/24 - Form S-8
- TRAW's page on the SEC website